Luciferase activity of ACE2-HEK293 cells transduced with Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase reporter).
Luciferase activity of ACE2-HEK293 cells transduced with Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase reporter).
Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
78784
Product group Molecular Biology
Overview
- SupplierBPS Bioscience
- Product NameSpike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
- Delivery Days Customer7
- CertificationResearch Use Only
- Scientific DescriptionThe Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain firefly luciferase driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by luciferase activity. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudoviruses can be used to measure the activity of a neutralizing antibody against the SARS-CoV-2 Omicron XBB.1.16 variant. The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951).
- Storage Instruction-80°C
- UNSPSC12352200